HK1154505A1 - 使多晶型現象最小化的方法 - Google Patents

使多晶型現象最小化的方法

Info

Publication number
HK1154505A1
HK1154505A1 HK11108783.1A HK11108783A HK1154505A1 HK 1154505 A1 HK1154505 A1 HK 1154505A1 HK 11108783 A HK11108783 A HK 11108783A HK 1154505 A1 HK1154505 A1 HK 1154505A1
Authority
HK
Hong Kong
Prior art keywords
polymorphism
minimize
minimize polymorphism
Prior art date
Application number
HK11108783.1A
Other languages
English (en)
Inventor
Simon A M Howes
Rosie Mclaughlin
Andrew Jordan
Wei Tian
Original Assignee
Rp Scherer Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rp Scherer Technologies Llc filed Critical Rp Scherer Technologies Llc
Publication of HK1154505A1 publication Critical patent/HK1154505A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK11108783.1A 2008-02-28 2011-08-19 使多晶型現象最小化的方法 HK1154505A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3229808P 2008-02-28 2008-02-28
PCT/US2009/035276 WO2009108775A2 (en) 2008-02-28 2009-02-26 Process to minimize polymorphism

Publications (1)

Publication Number Publication Date
HK1154505A1 true HK1154505A1 (zh) 2012-04-27

Family

ID=41016708

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11108783.1A HK1154505A1 (zh) 2008-02-28 2011-08-19 使多晶型現象最小化的方法

Country Status (19)

Country Link
US (1) US20090226522A1 (zh)
EP (1) EP2247284B1 (zh)
JP (2) JP5547096B2 (zh)
KR (1) KR101473419B1 (zh)
CN (2) CN102036655B (zh)
AR (1) AR072245A1 (zh)
AU (1) AU2009219292B2 (zh)
BR (1) BRPI0908539B8 (zh)
CA (1) CA2716901C (zh)
DK (1) DK2247284T3 (zh)
ES (1) ES2633928T3 (zh)
HK (1) HK1154505A1 (zh)
IL (2) IL207824A (zh)
MX (1) MX2010009493A (zh)
MY (1) MY173867A (zh)
NZ (1) NZ587611A (zh)
RU (1) RU2010139643A (zh)
WO (1) WO2009108775A2 (zh)
ZA (1) ZA201006421B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108434089B (zh) * 2010-10-08 2020-06-16 R·P·舍勒科技有限责任公司 使用淀粉的口服疫苗快速溶解剂型
PL3261645T3 (pl) 2015-02-27 2021-12-06 Dechra Limited Pobudzanie apetytu, zarządzanie utratą masy ciała, i leczenie anoreksji u psów i kotów
CN107951893B (zh) * 2016-10-18 2022-04-26 天津金耀集团有限公司 一种糠酸莫米松粉吸入剂组合物
FI3562486T3 (fi) 2016-12-31 2024-06-04 Bioxcel Therapeutics Inc Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa
KR20210028192A (ko) 2018-06-27 2021-03-11 바이오엑셀 테라퓨틱스 인코포레이티드 덱스메데토미딘을 함유하는 필름 제형 및 이를 생산하는 방법
CN109010295A (zh) * 2018-08-29 2018-12-18 北京兴源联合医药科技有限公司 一种左甲状腺素钠冻干口腔崩解片
CN109316452B (zh) * 2018-09-07 2021-07-30 北京兴源联合医药科技有限公司 一种硫酸氢氯吡格雷冻干口腔崩解片
SG11202108690YA (en) 2019-02-22 2021-09-29 Catalent Uk Swindon Zydis Ltd Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen
PL3927314T3 (pl) 2019-02-22 2024-02-19 Catalent U.K. Swindon Zydis Limited Minimalizacja aglomeracji materiału powlekającego cząstki leku podczas przechowywania dla ustabilizowania czasów rozpadu produktów farmaceutycznych
JP2022540706A (ja) 2019-07-19 2022-09-16 バイオエクセル セラピューティクス，インコーポレイテッド 鎮静作用のないデクスメデトミジン治療レジメン
CA3189404A1 (en) * 2020-07-31 2022-02-03 Catalent U.K. Swindon Zydis Limited Pharmaceutical compositions comprising coated api
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4946684A (en) * 1989-06-20 1990-08-07 American Home Products Corporation Fast dissolving dosage forms
DD289468B5 (de) 1989-11-07 1994-02-10 Dresden Arzneimittel Arzneimitteltechnologisches verfahren zur herstellung einer alprazolam-arzneiform
CA2020018A1 (en) * 1990-06-27 1991-12-28 Don L. Simmons Method and composition for treating the migraine complex
ATE216577T1 (de) * 1992-01-29 2002-05-15 Takeda Chemical Industries Ltd Schnellösliche tablette und ihre herstellung
US5631023A (en) * 1993-07-09 1997-05-20 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5457895A (en) * 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
CZ289649B6 (cs) 1994-07-22 2002-03-13 Krka, Tovarna Zdravil. P.O. Pevné lékové formy se spolehlivým uvolňováním aktivní sloľky alprazolamu a způsob jejich přípravy
JP2000508649A (ja) * 1996-04-16 2000-07-11 ノバルティス・コンシューマー・ヘルス・ソシエテ・アノニム 速崩解性経口剤形物
EP0839526A3 (en) * 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US6010719A (en) * 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
AU1380199A (en) * 1997-12-26 1999-07-19 Warner-Lambert Company Gelatine compositions
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6509040B1 (en) * 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
ES2284871T3 (es) 2001-06-22 2007-11-16 Pfizer Products Inc. Composiciones farmaceuticas que contienen una dispersion solida de farmaco poco soluble y un polimero potenciador de la solubilidad.
US7972621B2 (en) * 2004-06-03 2011-07-05 R.P. Scherer Technologies, Llc Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
US7855196B2 (en) * 2005-08-22 2010-12-21 Pierre Mainville Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist
EP1945227A4 (en) * 2005-11-09 2009-09-30 Dow Pharmaceutical Sciences AZITHROMYCIN FOR THE TREATMENT OF GRANULOMATOUS ROSACEA
GB0714223D0 (en) * 2007-07-20 2007-08-29 Fujifilm Mfg Europe Bv Preparation of fine particles

Also Published As

Publication number Publication date
CN102036655B (zh) 2013-11-20
AU2009219292A1 (en) 2009-09-03
RU2010139643A (ru) 2012-04-10
CN103751091B (zh) 2017-08-25
CA2716901C (en) 2018-07-03
WO2009108775A2 (en) 2009-09-03
ZA201006421B (en) 2011-05-25
MX2010009493A (es) 2010-12-20
IL252713A0 (en) 2017-08-31
WO2009108775A3 (en) 2009-12-03
DK2247284T3 (en) 2017-07-31
CA2716901A1 (en) 2009-09-03
JP2011513324A (ja) 2011-04-28
KR20100123740A (ko) 2010-11-24
US20090226522A1 (en) 2009-09-10
BRPI0908539B8 (pt) 2021-05-25
ES2633928T3 (es) 2017-09-26
EP2247284A2 (en) 2010-11-10
CN102036655A (zh) 2011-04-27
AR072245A1 (es) 2010-08-18
EP2247284B1 (en) 2017-04-19
IL207824A (en) 2017-11-30
EP2247284A4 (en) 2013-10-02
AU2009219292B2 (en) 2014-02-27
JP2014062119A (ja) 2014-04-10
IL207824A0 (en) 2010-12-30
BRPI0908539B1 (pt) 2020-12-08
NZ587611A (en) 2012-07-27
MY173867A (en) 2020-02-25
KR101473419B1 (ko) 2014-12-16
JP5547096B2 (ja) 2014-07-09
CN103751091A (zh) 2014-04-30

Similar Documents

Publication Publication Date Title
IL252713A0 (en) A process for reducing multiforms
GB0806422D0 (en) Process
GB0806419D0 (en) Process
GB0808836D0 (en) Process
GB0814519D0 (en) Process
GB0812742D0 (en) Process
GB0814053D0 (en) Process
GB0801209D0 (en) Process
GB0803669D0 (en) Process
GB0801580D0 (en) Process
GB0813598D0 (en) Process
GB0813433D0 (en) Process
GB0800875D0 (en) Process
GB0812400D0 (en) Process
GB0811851D0 (en) Process
GB0807161D0 (en) Process
GB0803960D0 (en) Process
GB0808764D0 (en) Process
GB0808357D0 (en) Process
GB0812919D0 (en) Process
GB0803663D0 (en) Process
GB0812098D0 (en) Process
GB0808359D0 (en) Process
GB0822880D0 (en) Novel process
GB0819739D0 (en) Novel process

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20240223